Literature DB >> 6870406

Hypercalcemia in prostatic carcinoma. Report of eight cases.

P S Mahadevia, A Ramaswamy, E S Greenwald, D I Wollner, D Markham.   

Abstract

Hypercalcemia is a rare complication of disseminated carcinoma of the prostate. To our knowledge, only three such patients have had their cases previously reported in the English language literature. Eight patients with prostatic cancer and hypercalcemia were seen at Montefiore Hospital and Medical Center, Bronx, NY, within the last six years. In six of the patients, the prostatic carcinoma exhibited unusual histologic patterns.

Entities:  

Mesh:

Year:  1983        PMID: 6870406

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

2.  Hypocalcemia in patients with prostate cancer.

Authors:  S C Kukreja; A Shanmugam; T E Lad
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

3.  Hypercalcaemia in a patient with non-secretory myeloma.

Authors:  D Chew; J R Playfer
Journal:  Postgrad Med J       Date:  1988-06       Impact factor: 2.401

4.  Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Authors:  Ana M Aparicio; Andrea L Harzstark; Paul G Corn; Sijin Wen; John C Araujo; Shi-Ming Tu; Lance C Pagliaro; Jeri Kim; Randall E Millikan; Charles Ryan; Nizar M Tannir; Amado J Zurita; Paul Mathew; Wadih Arap; Patricia Troncoso; Peter F Thall; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2013-05-06       Impact factor: 12.531

Review 5.  Androgen Receptor Signaling and the Emergence of Lethal Neuroendocrine Prostate Cancer With the Treatment-Induced Suppression of the Androgen Receptor: A Literature Review.

Authors:  Meera Dhavale; Mohamed K Abdelaal; A B M Nasibul Alam; Tatjana Blazin; Linha M Mohammed; Dhruvil Prajapati; Natalia P Ballestas; Jihan A Mostafa
Journal:  Cureus       Date:  2021-02-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.